Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Upcoming updates in multiple myeloma

Thierry Facon • 14 Jun 2019
EHA 2019
Multiple Myeloma Carfilzomib Daratumumab Isatuximab
GRIFFIN

Thierry Facon, MD, of Lille University Hospital, Lille, France, discusses trial results and what the future holds for multiple myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Thierry Facon

5:09
Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates
Thierry Facon • 14 Jun 2019
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon • 11 Dec 2018
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon • 11 Dec 2018
MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon • 6 Dec 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals